Nike Inc vs Personalis Inc. Common Stock — how do they compare? Nike Inc trades at $35.73 (market cap $52.48B), while Personalis Inc. Common Stock trades at $16.14 (market cap $1.69B). The key difference: Nike Inc is far larger — about 31.1× Personalis Inc. Common Stock's market cap, and Nike Inc pays a 4.64% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Personalis Inc. Common Stock for 0 Days on average.
| NKE | PSNL | |
|---|---|---|
Market Cap | $52.48B | $1.69B |
Volume | 30,189,626 | 3,817,236 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $18.38 |
52-Week Low | $33.87 | $5.04 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $55.18B | $1.52B |
Dividend Yield | 4.64% | — |
Signals from Pluang's Aura AI — not financial advice
NKE trades at $35.33, down slightly (-0.06%) on the day, with a bearish technical signal. The stock has a P/E of 16.9 and P/S of 1.14, trading below the analyst consensus price target of $36.80. Recent earnings have consistently beaten expectations, but revenue and net income have declined year-over-year. The company maintains strong brand equity but faces headwinds in key markets like China.
NKE's investment case hinges on its brand strength and potential for a turnaround, but near-term risks include sluggish consumer demand and margin pressure. The stock offers a dividend yield, but investors should weigh the execution risks of its strategic initiatives against its current valuation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →